This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
BD (BDX) Gears Up for Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences and Interventional segments is expected to have driven up Q1 sales.
Stryker (SYK) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Despite pandemic-led disruptions, Stryker's (SYK) fourth-quarter earnings reflect strong performance across its segments.
ResMed (RMD) Q2 Earnings in Line, Revenues Miss Estimates
by Zacks Equity Research
ResMed's (RMD) Q2 earnings meet estimates, with robust demand for sleep and respiratory care devices driving the top line.
McKesson (MCK) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.
Hologic (HOLX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Strength in Diagnostics and Breast Health businesses is likely to have contributed to Hologic's (HOLX) fiscal first-quarter revenues.
Abiomed (ABMD) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven up Q3 sales.
AmerisourceBergen (ABC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
CONMED's (CNMD) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
CONMED's (CNMD) fourth-quarter earnings reflect strong segmental performance.
Accuray (ARAY) Q2 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Accuray (ARAY) registers growth in Products revenues during fiscal Q2, thereby partly driving its overall top line.
NextGen Healthcare (NXGN) Beats on Q3 Earnings, Ups FY22 View
by Zacks Equity Research
NextGen Healthcare's (NXGN) fiscal third-quarter earnings reflect strength in both of its revenue sources.
Align Technology (ALGN) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Robust scanner shipments and an increase in Invisalign volumes within the teen segment are expected to have contributed to Align Technology's (ALGN) Q4 performance.
IDEXX (IDXX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Strong organic recurring revenue growth in the CAG diagnostics business and rise in new instrument placements are likely to have contributed to IDEXX's (IDXX) Q4 revenues.
Best Value Stocks to Buy for January 27th
by Zacks Equity Research
UMC, AMN, and FNB made it to the Zacks Rank #1 (Strong Buy) value stocks list on January 27, 2022
New Strong Buy Stocks for January 27th
by Zacks Equity Research
AMN, UMC, MRTN, FNB, and SLB have been added to the Zacks Rank #1 (Strong Buy) List on January 27, 2022.
Edwards Lifesciences (EW) Q4 Earnings Fall Shy of Estimates
by Zacks Equity Research
Strong sales growth across all four product groups along with increased adoption of the PASCAL platform drove Edwards Lifesciences' (EW) fourth-quarter revenues.
AMN Healthcare Services (AMN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed the most recent trading day at $96.13, moving -0.3% from the previous trading session.
Abbott's (ABT) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Abbott's (ABT) COVID-19 testing-related sales in Q4 increased on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
Here's Why You Should Add Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics' (DGX) improvement in base business and raised 2021 outlook.
Allscripts (MDRX) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Allscripts' (MDRX) revenue growth in the fourth quarter is likely to have been boosted by solid segmental performances.
Are These Medical Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
PerkinElmer (PKI) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results are likely to reflect strong performance at the Diagnostics segment.
Rise in COVID Tests to Boost Thermo Fisher (TMO) Q4 Earnings
by Zacks Equity Research
With the emergence of the Omicron variant through the Q4 months globally, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered strong top-line contributions.
STERIS (STE) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
The ongoing integration of Cantel Medical business and robust demand from medical device customers are expected to have contributed to STERIS' (STE) Q3 performance.
Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Biologics segment is likely to have maintained its impressive performance over the past few months, thereby aiding Q2 results.
SmileDirectClub (SDC) Moves up on New Strategic Actions
by Zacks Equity Research
SmileDirectClub's (SDC) new strategic actions are focused on supporting the key growth initiatives that will generate the highest return on investment.